King Debra sold $278K of SYK

King Debra (See Remarks) sold 826 shares of STRYKER CORP (SYK) at $336.30 ($0.28M total) on 2026-08-18.

Original reporting
SEC EDGAR · King Debra
Published Aug 18, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
medium confidence
Mentioned
$SYK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

The only new fact is the reported sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly reassess sentiment around SYK due to an insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing lacks any stated reason or linkage to company fundamentals.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-18

Background

The article is an SEC Form 4 insider transaction disclosure for Stryker (SYK).

Company-level read

Ticker impact

$SYKNeutralMedium confidence
Context

Stryker Form 4 shows officer King Debra sold 826 shares on 2026-08-18 at $336.3040, totaling $277,787.10.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction. The article provides transaction size, price, and post-sale holdings, but no new company-specific operational or financial information.

Market effects

No clear sector read-through from a single insider sale at this scale.

None.

None.

Counterpoint

Absence of a disclosed 10b5-1 plan can be interpreted by some traders as less “scheduled,” potentially adding short-term bearish sentiment.

Key entities

  • STRYKER CORP

    Company whose insider transaction was disclosed via Form 4.

  • King Debra

    Officer who sold 826 shares on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

$SYKHighAI 8/10

Stifel cuts Stryker stock price target on weak quarter, guidance

Stifel reduced its price target for Stryker (NYSE:SYK) to $325 from $330, maintaining a Buy rating after the company's Q3 results missed expectations. Stryker reported Q3 sales of $6.52B, below estimates, and lowered its full-year organic sales growth guidance to 6.5-7.0%. Multiple analysts have revised earnings downward, citing execution issues and market slowdowns.

$SYKHighAI 8/10

Stryker Earnings Call Balances Growth With Caution

Stryker Corp (SYK) reported Q3 earnings with 7.7% organic sales growth, 10.3% adjusted EPS increase to $3.52, and margin expansion. Growth was led by MedSurg and Neurotechnology, while Orthopaedics faced challenges. Management highlighted strong capital demand, innovation pipeline, and M&A activity, but acknowledged hip and knee market slowdowns and execution issues.